Background: Clear cell renal cell carcinoma (ccRCC) is an aggressive tumor with 50% risk
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INTRODUCTION
Renal cell carcinoma accounts for 3% of incidental solid tumors, of whom 70% to 75% are clear cell renal cell carcinomas (ccRCC) which are highly vascularized tumors. VHL is a major tumor suppressor gene involved in renal carcinogenesis. Alterations englobing its locus on chromosome 3p25-p26 in ccRCCs have been first described in patients with Von Hippel Lindau disease but VHL gene abnormalities are also observed in 60% to 70% of sporadic ccRCCs [1] [2] [3] . These genetic alterations are specific of the clear cell subtype and are typically not associated with other histological subtypes of renal carcinoma [4] .
At a cellular level, VHL acts as a tumor-suppressor gene. Its protein, pVHL, is a multifunctional protein insuring variable regulatory functions such as remodeling extra cellular matrix and controlling the cell cycle. The function that has been most thoroughly studied is the stability regulation of hypoxia inductible factor (HIF). pVHL is a component of an E3 ubiquitin-ligase which targets proteins, including the transcription factor HIF, leading to their ubiquitination and degradation by proteasomes. The consequence of pVHL impairment is a stabilization and increased level of HIF, leading to the transcription of genes regulated by HIF such as vascular endothelial growth factor (VEGF) or carbonic anhydrase IX (CAIX) [5] . Consequently, VHL acts as one of the main triggers of the angiogenic processes in ccRCC.
VHL gene impairments described in ccRCC necessarily involve biallelic alterations in tumor cells as both first and second "hits" must occur to be inactivated. These may reflect either mutations or deletions of the gene and/or hypermethylation of its promoter. One third of ccRCCs however exhibit no or a single allele alteration of VHL. Even if its key role is not In this study, we aimed to perform a detailed analysis of the VHL status in a retrospective cohort of ccRCCs in correlation with pathological criteria and long term clinical outcomes.
Our main goal was to seek differences in histological aspects depending on the complete VHL gene status. Our second objective was to verify if a given VHL group was associated with a worse prognosis, which was clinically relevant as the duration of our follow-up was a decade long.
MATERIALS AND METHODS

Patients
Patients operated for sporadic ccRCC in the Department of Urology at Rennes Hospital between 2002 and 2005 were retrospectively included. Care following surgery complied with standard recommendations for the given period, and patients' clinical conditions were monitored by the ECOG scale [6] . The study protocol was approved by the local advisory board and informed consent was obtained from each patient.
Tissue sample management
All consecutive and histologically validated ccRCCs were analyzed. Immediately after macroscopic examination, small samples were collected from surgical specimens and stored at -80°C until DNA extraction, using QIAamp DNA minikit (Qiagen, Courtaboeuf, France).
DNA quantity and quality were estimated by optical density (OD 260/280) measurement and 0,8% agarose gel electrophoresis using standard protocols.
Pathological analysis
After fresh tissue sampling, surgical specimens were formalin-fixed. Paraffin sections were stained with hematoxylin and eosin-safran. The analyzed parameters were: tumor size, multifocality, nuclear grade, sarcomatoid pattern, tumor necrosis, granular component, lymphocyte infiltrate and microvessel invasion. Tumor stage was defined according to the latest International Union Against Cancer 2009 classification [7] .
Immunochemistry
For each case, a representative slide of the tumor with the highest nuclear grade was selected.
VEGFA (Anti-VEGFA, sc-152; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and CAIX (Anti-CAIX, ab15086, Abcam, Cambridge, UK) expressions were assessed by immunohistochemistry. The cut-off for positive cases was 30% of tumor cells for VEGF and 85% for CAIX as previously described [8] [9] [10] . Negative control was performed by omitting the primary antibody. Regarding tumor infiltrating lymphocytes, CD3 (anti-CD3, clone SP7, dilution 1/100; Thermo Scientific, Waltham, MA, USA) and CD20 (anti-CD20, clone L26, dilution 1/25; Dako, Glostrup, Denmark) expressions were assessed. The inflammatory extent was coded as 1 (sparse and rare lymphocytes) or 2 (marked dense lymphocytes or lymphoid nodules). The reactivity of antibodies was revealed with HRP-labeled polymer conjugated secondary antibodies using diaminobenzidine (Sigma-Aldrich, France). Tumor expressions were independently evaluated without knowledge of patient outcome or VHL gene status (NRL).
VHL gene analysis
The detection of VHL mutations was performed by sequencing in denaturing high performance liquid chromatography (DHPLC). We amplified two overlapping fragments for exon 1 (1A and 1B) and one fragment for each of exons 2 and 3, covering part of the VHL-5'UTR, the entire coding sequence and exon-intron junctions (VHL Genbank accession AF010238) as previously described [11] . After purification, forward and reverse automatic sequencing was performed using BigDye Terminator v1.1 Cycling Sequencing kit on an ABI Prism 3100 Genetic Analyser (Applied Biosystems, Courtaboeuf, France). All mutations were confirmed in a second round of PCR and sequencing reactions.
Multiplex Ligation-dependent Probe Amplification (MLPA) analysis was used to detect deletions or duplications of the VHL gene with the SALSA MLPA P016B VHL probe kit (MRC-Holland, Amsterdam, Netherlands), targeting the three VHL exons.
After denaturation and probe hybridization, PCR was performed and fragments were separated by electrophoresis on an Applied 3130XL capillary sequencer and quantified using the GeneMarker version 1.6 software (SoftGenetics). For copy number detection, normal control DNA samples were included in each set of MLPA experiments. Interpretation was based on the comparison of peak heights between control DNA and the tumor sample. Cut-off levels for loss of relative copy number were set at 0.75.
Methylation-Specific-MLPA (MS-MLPA) was used to detect CpG methylation in the VHL gene promotor [12] . The probe design containing a methylation-sensitive restriction site (HhaI) allowed detecting aberrant methylation of CpG-islands located in the promoter region of the VHL gene using the SALSA MS-MLPA ME001B Tumor suppressor-1 kit.
Regarding tumor heterogeneity, we additionally performed VHL studies in 10 patients, in different tumor regions, revealing the same VHL status as initially described.
Statistical analysis
Chi2 and Student's tests were performed to compare qualitative and quantitative parameters respectively between groups. Multivariate analysis was then performed. Cancer specific survival was compared by log rank test and represented with Kaplan Meier curves. All analyses were conducted by AP with the Stata 11.1 (College Station, TX) software and the pvalue significance was fixed at 0,05.
RESULTS
Patients and histological parameters
The analysis retrospectively included 98 patients. The median age at diagnosis was 64 years (40-84). Sixty nine patients (70%) had an ECOG performance status of 0. In 11 cases Table 1 .
Genetic and epigenetic VHL gene alteration All patients were negative for germ-line mutations. A VHL gene mutation was found in 68 cases (69.4%). Mutations occurred in exons 1, 2 and 3 in 27 (27.6%), 27 (27.6%) and 14 cases (14.3%) respectively. Stop, frameshift, missense, and splice site mutations were found in 10 (10.2%), 33 (33.7%), 19 (19.4%) and 6 (6.1%) cases respectively. VHL loss of heterozygosity and promoter methylation occurred in 71 (72.4%) and 13 cases (13.3%) respectively. At least one or more VHL abnormalities were found in 87 cases (88.8%).
Tumors with 2 alterations of the VHL gene (n=65 cases, 66.3%) were termed inactivated for that gene (inVHL). Those with none or only one alteration (n=33, 33.7%) were grouped as activated VHL tumors (acVHL). These included tumors with no alteration of the VHL gene (n=11, 11,2%) that were termed wild type (wtVHL) (Figure 1 
Relationship between VHL gene alterations and survival
While no significant difference was observed concerning specific survival rates between acVHL and inVHL cases (p=0.078), the subgroup of wtVHL patients showed a separate evolution compared to both inVHL and patients with one VHL alteration (p=0.016), and separately compared to inVHL patients (p=0.009). The survival curves of the 3 subgroups (inVHL, acVHL with one alteration, and acVHL with no alteration-wtVHL) are illustrated in 
DISCUSSION
This is the first study to our knowledge, with a long term clinical follow-up of ten years that deals with histological differences between ccRCCs depending on their complete VHL status.
It shows the presence of three subgroups of tumors with different phenotypes and clinical outcomes. Clear cell renal cell carcinoma is a highly vascularized tumor, and the major gene implicated in its carcinogenesis at an early stage is VHL, a tumor suppressor gene that requires at least two events, one on each allele to be inactivated, as VHL is not a haploinsufficient tumor-suppressor gene. Deletion of the VHL gene locus was the most frequent event, 72.4% in our series which is less than the 91% loss of the 3p region observed in a recent cancer genome study [13] . In this same study, mutations of the VHL gene were observed in 52% of cases and promoter hypermethylations in 7% of tumors. Theses events are reported in a variable percentage in the literature, between 34% and 71% for mutations [14, 15] , and between 5% and 19% for promoter hypermethylations [16, 17] . We observed 69.4% and 14.2% of these events respectively. As expected, mutations and promoter methylations were mutually exclusive as no case exhibited the two events simultaneously.
Mutations of the exons 1 and 2 were more frequent than those of exon 3 and frameshift mutations were the most common types of mutational events. Tumors with 2 VHL hits (inVHL (2)) represented 66.3% of patients, which was more frequent than tumors with only one hit (acVHL (1), 22 .4%) and even more frequent than tumors with no VHL event (wtVHL (0), 11.2%).
VHL inactivation was associated with a better prognosis and this was illustrated by better survival rates, lower nuclear grade, less metastases, and less sarcomatoid component in this group of tumors than in acVHL tumors. Indeed, we observed that several factors were significantly associated with acVHL cases. In opposition to tumors with at least two alterations of the VHL gene, acVHL tumors were associated with higher nuclear 4 grade and metastases. Sarcomatoid component was also more frequent in this group. This parameter is a major and well known poor prognostic factor [18] , and our results are consistent with recent studies describing low HIF-1α expression (due to a functional pVHL protein: acVHL) in ccRCCs with a sarcomatoid component [19] .
Dense lymphocyte infiltrate was associated with acVHL tumors. In ccRCC, the intra-tumoral mononuclear infiltrate is associated with pejorative outcomes and higher nuclear grade [20] [21] [22] . For instance, binding of programmed death ligand 1 (PD-L1) expressed by tumor cells to the co-stimulatory receptor on T regulatory cells, PD-1, promotes inactivation and apoptosis of activated tumor specific T lymphocytes, and blockade of PD-1 or its ligand PD-L1 by specific antibodies produce objective responses in some cancers including renal cell carcinomas [23] [24] . This particularly dense lymphocyte infiltrate associated to acVHL tumors could be investigated looking for PD1-positive cells implicated in prognosis of ccRCCs and in PD1-based immunotherapy [25] . Surprisingly, the overexpression of VEGF was also independently associated with acVHL tumors and inversely correlated to the overexpression of CAIX. Both CAIX and VEGF are VHL/HIF downstream targets. However, unlike CAIX, which is a surrogate indicator for VHL status, VEGF regulation is much more complex. These results support the theory of alternative oncogenic pathways in ccRCC leading to VEGF overexpression despite HIF degradation due to the presence of an activated VHL protein (acVHL). Tumors with no inactivation of VHL could use alternative pathways independent from VHL mechanisms and lead to VEGF overexpression promoting tumor angiogenesis. These alternative pathways [26] [27] [28] [29] [30] , that include the MAP kinase and the PI3K-AKT-mTOR pathways, may be potentially implicated in the resistance to targeted therapy by tyrosine kinase inhibitors.
Furthermore, the subgroup of wtVHL tumors was clearly of worse prognosis as demonstrated by significant poorer specific survival rates. In our study, clinical outcomes did not significantly differ between the first two groups (inVHL and acVHL with one event).
However, the group of patients with wtVHL exhibited significant worse outcomes: 73% of wtVHL patients died from their cancer at the end of follow-up, compared to 45% of patients with one VHL alteration and 40% of patients with inVHL tumors.
The limitations to this study, besides the small number of wild type cases, are the variation of treatment given to metastatic patients at the time before full market approval of proteintyrosine kinase inhibitors as a first-line drug; similarly to all studies realized on kidney cancer at that time. The other limitation is the high frequency of metastatic patients in the wild type group, disabling us from excluding metastatic patients from the analysis, and which does not allow a metastatic-independent evaluation of mortality.
CONCLUSIONS
This study shows the existence of three groups of ccRCCs depending on their VHL status. The wtVHL subgroup is a separate entity of worse prognosis. The wider perspective of this study is to increase these cases that represent only 10% of ccRCCs for a better molecular characterization and the study of wtVHL tumors in non-metastatic patients. Such an increase would enable us to dig further in what makes these tumors so specific and more aggressive, and in why VEGF remains at high levels of expression, despite a VHL protein that is intact.
These tumors could be screened more thoroughly and studied as factors of resistance or sensitivity to targeted therapy. Other types of specific therapies targeting alternative pathways of VEGF may be useful in treating these patients. 
